Agomab Therapeutics NV

AGMB · NASDAQ

$9.05−$0.21 (−2.27%)TodayMarket closed ·
Prev close $9.26

About AGMB

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. The firm is engaged in research and development services creating therapies for fibrotic and inflammatory diseases. Its activities include discovery research to identify drug candidates that act on pathways involved in fibrosis and tissue repair, such as organ restricted small molecules and growth factor targeting antibodies. The firm also carries out preclinical development, including work on programs, to evaluate drug behavior and readiness before entering human studies. In addition, It conducts clinical development services by sponsoring and managing trials for its pipeline, assessing safety, tolerability, pharmacokinetics, and pharmacodynamics.

Employees
62
Headquarters
Antwerp, Bruxelles-Capitale
Listed
Feb 6, 2026
Sector
Health Care
Industry
Pharmaceuticals
Website
agomab.com

Leadership

Agomab Therapeutics NV executives
NameTitleSince
David Epstein——
Tim Knotnerus—2019
Pierre Kemula——
Ellen Lefever——
Andrea Saez——
Paul van der Horst——
Philippe Wiesel——
Colin Bond——
Ohad Hammer——
Angelika Jahreis——
Felice Verduyn-van Weegen——

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.